



COLUMNISTA

Coluna do Broadcast

Verdemed purchases laboratory and plans to invest US\$10 million in Brazil in 2019

Coluna do Broadcast

June 23, 2019 | 09:26

Verdemed, a Canadian cannabinoid-based pharmaceutical company, has acquired the Mydstein laboratory in São Paulo for US\$1 million. However, the company's plans for the Brazilian market go further. Its current objective is to invest US\$10 million through the end of this year to expand the sale of cannabis-based medicines (medical marijuana) in Brazil.

Expansion. With operations in Canada, Chile, Colombia and Brazil, Verdemed is planning to enter Argentina, Mexico and Peru this year. Its longer-term objective is to invest US\$80 million in Latin America by 2022.

Contact:

colunadobroadcast@estadao.com

Follow @colunadobroadcast on Twitter



VerdeMed

To see Coluna do Broadcast any time, subscribe to Broadcast +

<https://economia.estadao.com.br/blogs/coluna-do-broad/verdemed-compra-laboratorio-e-preve-us-10-mi-no-brasil-em-2019/>